NCT02933190

Brief Summary

To investigate the fertility in patients after treatment by transvaginal surgery or uterine artery embolization combined with uterine curettage

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 9, 2016

Completed
2 months until next milestone

First Posted

Study publicly available on registry

October 14, 2016

Completed
18 days until next milestone

Study Start

First participant enrolled

November 1, 2016

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2018

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

October 14, 2016

Status Verified

August 1, 2016

Enrollment Period

1.7 years

First QC Date

August 9, 2016

Last Update Submit

October 12, 2016

Conditions

Outcome Measures

Primary Outcomes (3)

  • Duration of menstruation by questionnaire (days)

    six months after treatment

  • Endocrine level by blood examination (FSH in IU/L)

    six months after treatment

  • Volume of menstruation by questionnaire (in pictorial blood loss score)

    six months after treatment

Secondary Outcomes (3)

  • The length of the CSD by MRI (millimeter)

    six months after treatment

  • The width of the CSD by MRI (millimeter)

    six months after treatment

  • The depth of the CSD by MRI (millimeter)

    six months after treatment

Study Arms (1)

CSP;transvaginal surgery;UAE and D&C

OTHER

Cesarean scar pregnancy (CSP) refers to the implantation of a gestational sac with the myometrium at the site of a previous cesarean scar

Procedure: transvaginal surgery;UAE and D&C

Interventions

For cesarean scar pregnancy treatment

CSP;transvaginal surgery;UAE and D&C

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • increased levels of serum β-hCG and ultrasonography findings. The criteria for diagnosis by ultrasonography was the presence of the following: (1) an empty uterine cavity and endocervical canal; (2) detection of the placenta and/or a gestational sac embedded in the hysterectomy scar; (3) the presence of the gestation sac with or without a fetal pole and with or without fetal cardiac activity (depending on the gestational age) in the anterior part of the uterine isthmus; and (4) a thin (1-3 mm) or absent myometrial layer between the gestational sac and the bladder(24). All patients had taken Magnetic Resonance Imaging (MRI) to clarify the diagnosis . Pregnancy tissues were identified by histopathology examinations of the surgical tissues.

You may not qualify if:

  • All enrolled patients had no contraindications for transvaginal surgery or UAE, including renal failure, active pelvic infection, clotting disorders, or known allergy to the contrast material.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Gynecology, Shanghai First Maternity and Infant Hospital, affiliated to Tongji University

Shanghai, Shanghai Municipality, 201204, China

Location

MeSH Terms

Interventions

Dilatation and Curettage

Intervention Hierarchy (Ancestors)

CurettageSurgical Procedures, OperativeGynecologic Surgical ProceduresUrogenital Surgical Procedures

Study Officials

  • Xipeng Wang

    Department of Gynecology, Shanghai First Maternity and Infant Hospital, affiliated to Tongji University

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 9, 2016

First Posted

October 14, 2016

Study Start

November 1, 2016

Primary Completion

August 1, 2018

Study Completion

December 1, 2019

Last Updated

October 14, 2016

Record last verified: 2016-08

Locations